Floatz logo

int230-6

Triple-negative Breast Cancer

Swiss Cancer InstitutePhase 2Active
CCC
53/ 100
Provisional rating · Methodology v0.2

Rating breakdown

Clinical Evidence
38/ 100
Competitive Position
81/ 100

Competitive context

447 Active assets in the Triple-negative Breast Cancer cohort.

Asset / SponsorPhaseRating
Capivasertib
AstraZeneca
Phase 3BB
Carboplatin
M.D. Anderson Cancer Center
Phase 4BB
Cyclophosphamide
M.D. Anderson Cancer Center
Phase 4BB
Veliparib
National Cancer Institute (NCI)
Phase 3BB
Enzalutamide
Nuvation Bio Inc.
Phase 2BB

View all 50 →

Same molecule, other indications

int230-6 is also rated in:

breast cancerDormant
CCC
Indicative ·
53 / 100
View asset →
sacrum chordomaDormant
CCC
Indicative ·
52 / 100
View asset →
TNBC - Triple-Negative Breast CancerDormant
CCC
Indicative ·
51 / 100
View asset →

Need depth?

Order a full diligence report on this asset.

Order report →

Are you the sponsor?

Submit your data room for a Verified Rating. The public-data rating remains visible alongside.

Contact →